An Open-Label, Phase 2b Global Multicenter Cohort Trial of Zipalertinib in Locally Advanced or Metastatic NSCLC with Exon 20 Insertion and Uncommon/Single or Compound EGFR Mutations
September 11, 2026
A Multicenter, Randomized, Double-Blind, Adaptive Phase 2/3 Study of EIK1001 and Pembrolizumab vs Placebo and Pembrolizumab as First-Line Therapy in Advanced Melanoma